You are here: Industry Insights > Biogen

News List

Fujifilm Completes Acquisition of Biogen’s Manufacturing Site in Denmark contractpharma
August 05, 2019
Invests roughly $890 million in project.
Fujifilm completes acquisition of Biogen's Manufacturing Site in Denmark biospectrumasia
August 04, 2019
With the closing of this transaction, the Hillerød Manufacturing site is now the fourth biopharmaceutical manufacturing site of FUJIFILM Diosynth Biotechnologies
Biogen keeps its foot on the pedal in biosims as Humira copycat takes 'market-leading' position fiercepharma
July 28, 2019
Biogen may face uncertainty in multiple sclerosis, a new rival to its quick-launching SMA blockbuster, and setbacks in its pipeline, but its biosimilars group is zooming ahead.
Biogen secures extended access agreement for Spinraza pharmaceutical-technology
July 08, 2019
The UK’s National Health Service (NHS) has extended a managed access agreement (MAA) that covers the funding of Biogen’s spinal muscular atrophy (SMA) medication Spinraza (nusinersen).
With 'remarkable' data, Biogen's Spinraza sharpens its case against Novartis gene therapy fiercepharma
July 04, 2019
Biogen credited spinal muscular atrophy (SMA) drug Spinraza as its main growth driver last year, and the company aims to keep it that way—even in the face of new competition from Novartis gene therapy Zolgensma.
Who's the next Big Pharma takeout target? Biogen, uniQure, AZ top the list fiercepharma
June 28, 2019
Investors were none too pleased with AbbVie’s planned $63 billion buyout of Allergan, which they made clear by shaving $18 billion off the acquirer’s market cap by the end of the day Tuesday.
Biogen completes Nightstar acquisition pharmatimes
June 11, 2019
Biogen has announced that it has completed its acquisition of Sycona’s Nightstar Therapeutics, the clinical-stage gene therapy company, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders.
Biogen Completes $800M Nightstar Acquisition contractpharma
June 10, 2019
Gains two mid- to late-stage clinical assets and preclinical programs in ophthalmology.
Biogen's board expansion hits snag as Catalent CEO John Chiminski drops out biospectrumasia
May 29, 2019
With its Alzheimer's trial flop still smarting, Biogen's infusing new blood into its board. But now, one nominee for the expanded slate is bowing out.
Biogen’s SMA drug Spinraza to be available on NHS pharmaceutical-technology
May 22, 2019
The UK’s National Health Service (NHS) has signed a managed access agreement to fund Biogen’s antisense oligonucleotide (ASO) Spinraza (nusinersen) for a limited time to ascertain its effectiveness as a treatment for 5q spinal muscular atrophy (SMA).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page